Literature DB >> 27990078

Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia.

Donald C Moore.   

Abstract

Rituximab can cause late-onset neutropenia that may result in serious life-threatening complications. The author describes the pathophysiology, incidence, and management of this adverse reaction and presents two case histories.

Entities:  

Year:  2016        PMID： 27990078      PMCID： PMC5132417     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  16 in total

1.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 2.  Rituximab-associated neutropenia.

Authors:  Kieron Dunleavy; Kevin Tay; Wyndham H Wilson
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

3.  Relative incidence of agranulocytosis and aplastic anemia.

Authors:  David W Kaufman; Judith P Kelly; Surapol Issaragrisil; Joan-Ramon Laporte; Theresa Anderson; Micha Levy; Samuel Shapiro; Neal S Young
Journal:  Am J Hematol       Date:  2006-01       Impact factor: 10.047

Review 4.  Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review.

Authors:  Susannah E Motl; Reed C Baskin
Journal:  Pharmacotherapy       Date:  2005-08       Impact factor: 4.705

5.  Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma.

Authors:  Kenji Fukuno; Hisashi Tsurumi; Nobuhiro Ando; Nobuhiro Kanemura; Hideko Goto; Shinobu Tanabashi; Kiyonao Okamoto; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

6.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

Review 7.  Neutropenia associated with rituximab therapy.

Authors:  Cliona Grant; Wyndham H Wilson; Kieron Dunleavy
Journal:  Curr Opin Hematol       Date:  2011-01       Impact factor: 3.284

8.  Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab.

Authors:  Yasuo Hirayama; Kyuhei Kohda; Yuichi Konuma; Yasuji Hirata; Hiroyuki Kuroda; Yuko Fujimi; Sayaka Shirao; Masayoshi Kobune; Rishu Takimoto; Takuya Matsunaga; Junji Kato
Journal:  Intern Med       Date:  2009-01-01       Impact factor: 1.271

Review 9.  The mechanisms of action of rituximab in the elimination of tumor cells.

Authors:  Peter Johnson; Martin Glennie
Journal:  Semin Oncol       Date:  2003-02       Impact factor: 4.929

10.  Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.

Authors:  J H Salmon; P Cacoub; B Combe; J Sibilia; B Pallot-Prades; O Fain; A Cantagrel; M Dougados; E Andres; O Meyer; P Carli; E Pertuiset; I Pane; F Maurier; P Ravaud; X Mariette; J E Gottenberg
Journal:  RMD Open       Date:  2015-06-30
View more
  11 in total

1.  Kinesin-5 Blocker Monastrol Protects Against Bortezomib-Induced Peripheral Neurotoxicity.

Authors:  Ilja Bobylev; Dominik Peters; Maulik Vyas; Mohammed Barham; Ines Klein; Elke Pogge von Strandmann; Wolfram F Neiss; Helmar C Lehmann
Journal:  Neurotox Res       Date:  2017-06-13       Impact factor: 3.911

Review 2.  Immune-Mediated Cytopenias After Hematopoietic Cell Transplantation: Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment Strategies.

Authors:  Thomas F Michniacki; Christen L Ebens; Sung Won Choi
Journal:  Curr Oncol Rep       Date:  2019-08-15       Impact factor: 5.075

3.  Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.

Authors:  Roberto A Abbiati; Michael Pourdehnad; Soraya Carrancio; Daniel W Pierce; Shailaja Kasibhatla; Mark McConnell; Matthew W B Trotter; Remco Loos; Cristina C Santini; Alexander V Ratushny
Journal:  AAPS J       Date:  2021-08-27       Impact factor: 4.009

4.  Severe Delayed-Onset Neutropenia Induced by Ocrelizumab.

Authors:  Jonatha Baird-Gunning; James Yun; William Stevenson; Karl Ng
Journal:  Neurohospitalist       Date:  2020-07-09

5.  Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada.

Authors:  Graeme Ball; Feng Xie; Jean-Eric Tarride
Journal:  Pharmacoecon Open       Date:  2018-03

6.  Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome.

Authors:  George E Fragoulis; Caron Paterson; Ashley Gilmour; Mohammad H Derakhshan; Iain B McInnes; Duncan Porter; Stefan Siebert
Journal:  RMD Open       Date:  2018-10-08

Review 7.  Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?

Authors:  Elisa Lucchini; Francesco Zaja; James Bussel
Journal:  Haematologica       Date:  2019-05-24       Impact factor: 9.941

8.  Comparison of Hematological and Biochemical Profile Changes in Pre- and Post-Chemotherapy Treatment of Cancer Patients Attended at Ayder Comprehensive Specialized Hospital, Mekelle, Northern Ethiopia 2019: A Retrospective Cohort Study.

Authors:  Bayu Wondimneh; Sathisha Anekere Dasappa Setty; Gebrekidan Gebregzabher Asfeha; Ezra Belay; Gidey Gebremeskel; Gelagay Baye
Journal:  Cancer Manag Res       Date:  2021-01-22       Impact factor: 3.989

9.  Machine learning optimized polygenic scores for blood cell traits identify sex-specific trajectories and genetic correlations with disease.

Authors:  Yu Xu; Dragana Vuckovic; Scott C Ritchie; Parsa Akbari; Tao Jiang; Jason Grealey; Adam S Butterworth; Willem H Ouwehand; David J Roberts; Emanuele Di Angelantonio; John Danesh; Nicole Soranzo; Michael Inouye
Journal:  Cell Genom       Date:  2022-01-12

10.  Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine.

Authors:  Ramon Diez-Feijóo; Juan Jose Rodríguez-Sevilla; Concepcion Fernández-Rodríguez; Solange Flores; Carmen Raya; Ana Ferrer; Luis Colomo; Antonio Salar
Journal:  Front Immunol       Date:  2022-01-10       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.